Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients
,
2021 – Sandoz, a global leader in biosimilar and generic medicines, today announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi
® (etanercept-szzs) for reference medicine Enbrel
® (etanercept). The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen’s patents.
“We are disappointed the Supreme Court decided not to review our case,” said Keren Haruvi, President of Sandoz US and Head of North America. “Today’s decision means Erelzi, a more affordable biosimilar, will not be available to US patients with autoimmune and inflammatory diseases until 2029; nonetheless we remain committed to providing important treatment options for patients affected by these diseases.”
Photo: Thirdman/Pexels
When the COVID-19 pandemic kicked off, everyone expected India to supply the bulk of the vaccines to poorer countries – in keeping with its image as ‘the pharmacy of the world’. India also appeared to accept this challenge quite willingly. However, the Indian government soon seemed to be treating the task of vaccinating almost 1.4 billion Indians like an elephant in the room.
The dramatic turnaround in India’s approach that soon followed – from flaunting its credentials as ‘saviour’ of the world to ‘stopping exports’ against legal agreements – triggered alarm. When and how this situation will be resolved is unclear at the moment.
. (Tribune News Service) Before the coronavirus vaccines had even been proven to work, the United States scrambled to pre-order hundreds of millions of doses. The government has paid billions to Pfizer, Moderna and other vaccine makers so that every person in the country can get vaccinated free of charge. It doesn’t matter if you’re uninsured, undocumented, don’t have a regular doctor or a driver’s license. In the interest of taming the pandemic, the government did away with some of the biggest barriers people often face in accessing health care. Industry analysts and patient advocates are keeping a close eye on what happens next: If, once the federal health emergency has ended, the government stops bulk-buying the vaccine, costs could go up and people who are uninsured may be at risk of going without. Or perhaps the government’s approach to COVID-19 vaccination could lead the way to drug price reform that would allow federal programs, such as Medicare, to negotiate
Pharmaceutical companies that invested in coronavirus vaccine development will see big revenues.
May 4th, 2021
It’s seldom that drug companies have the opportunity to develop a product that’s relevant to the entire world. In fact, it takes a global pandemic. IQVIA Institute for Human Data Science took on the task of estimating the financial impact of protecting the population from COVID-19, and the numbers are staggering. According to a recent
FiercePharmaarticle that discussed the figures, global vaccine sales will reach $157B by 2025. This estimate accounts for dramatic drops in the cost per dose going from an average of $22 per shot in 2021 to $9 per shot in 2023.